MPD: Phenotype measures mapped to VT:0015058, brain physiology trait

Phenotype measures associated with ontology term
VT:0015058 'brain physiology trait'

This list includes measures mapped VT:0015058 AND its ontology descendants. Alternatively, you can show measures mapped to VT:0015058 only.

VT:0001895 hippocampus physiology trait
VT:0001907 cerebellum physiology trait

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Crabbe2:1	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, 30 min post-injection [ng/g] brain_DZ 15501 8 mg/kg 16 mg/kg	inbred	15	m	6-7wks	N=8	1998

Crabbe2:3	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, <5 min post-injection, after rotarod [ng/g] brain_DZ20 15503 trial block1 trial block2	inbred	15	m	6-7wks	N=13	1998

Frankel1:1	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for minimal clonic seizure, frontal stimulation (at BH) [mA] E_MC_BH_FS 5601	inbred	4	m	6-11wks	N=35	2000

Frankel1:2	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at BH) [mA] E_MC_BH_TC 5602	inbred	16	both	6-11wks	N=33	2000

Frankel1:3	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at SL) [mA] E_MC_SL_TC 5603	inbred	8	both	6-11wks	N=29	2000

Frankel1:4	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, frontal stimulation (at BH) [mA] E_MT_BH_FS 5604	inbred	4	m	6-11wks	N=44	2000

Frankel1:5	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at BH) [mA] E_MT_BH_TC 5605	inbred	16	both	6-11wks	N=38	2000

Frankel1:6	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at SL) [mA] E_MT_SL_TC 5606	inbred	8	both	6-11wks	N=29	2000

Frankel1:7	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, frontal stimulation (at BH) [mA] E_PS_BH_FS 5607	inbred	4	m	6-11wks	N=41	2000

Frankel1:8	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at BH) [mA] E_PS_BH_TC 5608	inbred	14	both	6-11wks	N=41	2000

Frankel1:9	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at SL) [mA] E_PS_SL_TC 5609	inbred	7	both	6-11wks	N=39	2000

Frankel1:10	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MC_BH_TC 5610	inbred	3	m	6-11wks	N=63	2000

Frankel1:12	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MC_SL_TC 5612	inbred	3	m	6-11wks	N=51	2000

Frankel1:13	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MT_BH_TC 5613	inbred	3	m	6-11wks	N=52	2000

Frankel1:14	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MT_SL_TC 5614	inbred	3	m	6-11wks	N=45	2000

JaxKOMP-EAP:399	JaxKOMP-EAP	electroconvulsion test	(none)	applied stimulus (current), by day [mA] current ma 100783 day: 1 2 3 4 5 6 7 8 9 10	KOMP	23	both	17wks	N=8	2016

JaxKOMP-EAP:409	JaxKOMP-EAP	electroconvulsion test	(none)	behavior following applied stimulus (current), by day [score] score 100784 day: 1 2 3 4 5 6 7 8 9 10	KOMP	448	both	17wks	N=9	2016

JaxKOMP-EAP:419	JaxKOMP-EAP	electroconvulsion test	(none)	stimulus level (current) required for minimal clonic forebrain seizure (score of 3 or higher) [mA] threshold ma_threshold 100813	KOMP	479	both	17wks	N=9	2016

Mooney1:1	Mooney1	protein activity assessment	(none)	cerebellum acetylcholinesterase activity [mU/mL] CB_AChE 110424	inbred	20	m	8-12wks	N=6	2019

Mooney1:2	Mooney1	protein activity assessment	(none)	dorsal hippocampus acetylcholinesterase activity [mU/mL] DH_AChE 110425	inbred	20	m	8-12wks	N=6	2019

Mooney1:3	Mooney1	protein activity assessment	(none)	ventral hippocampus acetylcholinesterase activity [mU/mL] VH_AChE 110426	inbred	20	m	8-12wks	N=6	2019

Schalkwyk2:1	Schalkwyk2	RNA expression profiling	(none)	miR-15b, hippocampal microRNA expression, relative miR15b 48101	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:2	Schalkwyk2	RNA expression profiling	(none)	miR-31, hippocampal microRNA expression, relative miR31 48102	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:3	Schalkwyk2	RNA expression profiling	(none)	miR-34c, hippocampal microRNA expression, relative miR34c 48103	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:4	Schalkwyk2	RNA expression profiling	(none)	miR-212, hippocampal microRNA expression, relative miR212 48104	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:5	Schalkwyk2	RNA expression profiling	(none)	miR-301a, hippocampal microRNA expression, relative miR301a 48105	BXD w/par	26	m	15-16wks	N=4	2012

Schauwecker1:1	Schauwecker1	health assessment	pilocarpine	pilocarpine dose required to induce status epilepticus, mg/kg body weight [mg/kg] ED100 47701	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:2	Schauwecker1	health assessment	pilocarpine	latency to onset of stage 4 status epilepticus seizures [min] latency 47702	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:3	Schauwecker1	health assessment	pilocarpine	duration of stage 4 status epilepticus seizures [min] duration 47703	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:4	Schauwecker1	health assessment	pilocarpine	status epilepticus seizure mortality (0=died; 1=survived) [designation] survival 47704	inbred	11	m	8-10wks	N=18	2012

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:22	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:25	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:37	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:40	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:43	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:46	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:52	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:58	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:67	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:73	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Filter Table Results